3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
7
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Refractory or Relapsed Solid Tumors
1
Prostatic Neoplasms, Castration-Resistant
1
Non-metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Bulbo-Spinal Atrophy, X-Linked
1
Biochemically Recurrent Prostate Cancer
1
Adenocarcinoma
1
Interventions
Prednisone
4
Docetaxel
4
enzalutamide
2
olaparib
1
niraparib
1
ibrutinib
1
fludrocortisone acetate
1
darolutamide
1
cabazitaxel
1
abiraterone
1
Rosuvastatin Calcium
1
Pluvicto
1
Pioglitazone
1
JNJ-64619178
1
JNJ-64264681
1
Dexamethasone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms, Castration-Resistant
×
darolutamide
×
30 days
×
Clear all
NCT05997615
2026-06-04
AMX-500
Vir Biotechnology, Inc.
Phase 1
Recruiting
437 enrolled